← All trials
NCT05325281
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 31, 2022
- Primary completion
- Aug 31, 2026
- Completion date
- Aug 31, 2027
- First posted
- Apr 13, 2022
- Last posted
- Nov 14, 2022
- Enrollment
- 24
- Arms / groups
- 5 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Medical College of WisconsinLead sponsor
- Medical College of WisconsinOverall official - principal investigator
- Medical College of WisconsinReponsible party - principal investigator
- Rafael Pharmaceuticals Inc.Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.